December 8, 2015Open Access

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion. (Funded by the Acerta Pharma and others; ClinicalTrials.gov number, NCT02029443.).

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Byrd et al. (Tue,) studied this question.

synapsesocial.com/papers/69dcc8e07873f5f05b134072 https://doi.org/https://doi.org/10.1056/nejmoa1509981

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines2008 · 3,193 citations
2Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)2013 · 45 citations
3Tec is involved in G protein-coupled receptor- and integrin-mediated signalings in human blood platelets1998 · 39 citations
4The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia2010 · 816 citations
5Nonparametric Estimation from Incomplete Observations1992 · 45,550 citations

Me gusta

Guardar

Ver artículo completo